Cohort profile: the hepatitis C virus (HCV) Research UK clinical database and biobank

John McLauchlan, Hamish Innes, John Dillon, Graham Foster, Elizabeth Holtman, Sarah McDonald, Bryony Wilkes, Sharon Hutchinson, Will Irving

Research output: Contribution to journalArticle

26 Downloads (Pure)

Abstract

Cohort purpose: Chronic hepatitis C Virus (HCV) infection is a leading cause of liver disease, both in the UK and world-wide. The HCV Research UK clinical database and biobank was set up to tackle key gaps in our understanding of infection, particularly in relation to: the effectiveness and long-term impact of antiviral therapies; and the genetic/virological factors influencing the natural history of infection.
Cohort Basics: The cohort comprises in excess of 10,000 participants. Each participant was enrolled between March 2012 and July 2015 following attendance at one of 56 specialist HCV clinics in the UK. The mean age at baseline is 48.5 years (range 0-88 years).
Follow-up and attrition: A core set of follow-up data (covering health risk behaviours, physical characteristics, comorbidities, virology, co-medications, liver disease status, antiviral treatment and mortality status) will be collected from participants biennially. Additional follow-up data is being sought for strategic subgroups (e.g. selected participants with advanced liver disease).
Design and Measures: This is a longitudinal cohort study. Baseline clinical and epidemiological data were collected through a standardised questionnaire completed by each participant at their enrolment. Follow-up data is elicited mainly through assessment of patient medical notes.
Unique features: Participant blood samples have been stored in a biorespository and are available for research studies. Thus far, full-length next-generation sequencing of viral RNA, and host genotyping has been carried out in ~2000 and ~4000 cohort participants respectively. These data can be linked to the clinical/epidemiological data collected at baseline and follow-up.
Reasons to be cautious: Participants included in this cohort represent ~50% of all patients in attendance at the selected recruitment clinics. Potentially, participants may differ from non-participants in epidemiologically/clinically relevant ways.
Collaboration and data access : Data and samples are accessible to researchers following successful application to the HCV Research UK Tissue and Data Access Committee (TDAC). More information on the TDAC application process can be found at the HCV Research UK website - www.hcvresearchuk.org.
Original languageEnglish
Pages (from-to)1391-1391h
Number of pages9
JournalInternational Journal of Epidemiology
Volume46
Issue number5
Early online date27 Feb 2017
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Hepacivirus
Databases
Liver Diseases
Research
Antiviral Agents
Virology
Viral RNA
Chronic Hepatitis C
Virus Diseases
Risk-Taking
Infection
Longitudinal Studies
Comorbidity
Cohort Studies
Research Personnel
Mortality
Health
Therapeutics

Keywords

  • hepatitis C
  • biobank
  • liver disease
  • host genomics
  • cohort
  • clinical database

Cite this

McLauchlan, J., Innes, H., Dillon, J., Foster, G., Holtman, E., McDonald, S., ... Irving, W. (2017). Cohort profile: the hepatitis C virus (HCV) Research UK clinical database and biobank. International Journal of Epidemiology, 46(5), 1391-1391h. https://doi.org/10.1093/ije/dyw362
McLauchlan, John ; Innes, Hamish ; Dillon, John ; Foster, Graham ; Holtman, Elizabeth ; McDonald, Sarah ; Wilkes, Bryony ; Hutchinson, Sharon ; Irving, Will . / Cohort profile: the hepatitis C virus (HCV) Research UK clinical database and biobank. In: International Journal of Epidemiology. 2017 ; Vol. 46, No. 5. pp. 1391-1391h.
@article{2c8065538ac446c38c9e5abb3a729434,
title = "Cohort profile: the hepatitis C virus (HCV) Research UK clinical database and biobank",
abstract = "Cohort purpose: Chronic hepatitis C Virus (HCV) infection is a leading cause of liver disease, both in the UK and world-wide. The HCV Research UK clinical database and biobank was set up to tackle key gaps in our understanding of infection, particularly in relation to: the effectiveness and long-term impact of antiviral therapies; and the genetic/virological factors influencing the natural history of infection.Cohort Basics: The cohort comprises in excess of 10,000 participants. Each participant was enrolled between March 2012 and July 2015 following attendance at one of 56 specialist HCV clinics in the UK. The mean age at baseline is 48.5 years (range 0-88 years).Follow-up and attrition: A core set of follow-up data (covering health risk behaviours, physical characteristics, comorbidities, virology, co-medications, liver disease status, antiviral treatment and mortality status) will be collected from participants biennially. Additional follow-up data is being sought for strategic subgroups (e.g. selected participants with advanced liver disease). Design and Measures: This is a longitudinal cohort study. Baseline clinical and epidemiological data were collected through a standardised questionnaire completed by each participant at their enrolment. Follow-up data is elicited mainly through assessment of patient medical notes.Unique features: Participant blood samples have been stored in a biorespository and are available for research studies. Thus far, full-length next-generation sequencing of viral RNA, and host genotyping has been carried out in ~2000 and ~4000 cohort participants respectively. These data can be linked to the clinical/epidemiological data collected at baseline and follow-up.Reasons to be cautious: Participants included in this cohort represent ~50{\%} of all patients in attendance at the selected recruitment clinics. Potentially, participants may differ from non-participants in epidemiologically/clinically relevant ways.Collaboration and data access : Data and samples are accessible to researchers following successful application to the HCV Research UK Tissue and Data Access Committee (TDAC). More information on the TDAC application process can be found at the HCV Research UK website - www.hcvresearchuk.org.",
keywords = "hepatitis C, biobank, liver disease, host genomics, cohort, clinical database",
author = "John McLauchlan and Hamish Innes and John Dillon and Graham Foster and Elizabeth Holtman and Sarah McDonald and Bryony Wilkes and Sharon Hutchinson and Will Irving",
note = "Need to merge docs and re-upload Author confirmed version is AAM 23-1-17 Update: VoR uploaded as OA article ET 12-5-17 Funding to support this initiative was provided by the Medical Research Foundation, the independent charity of the UK Medical Research Council. HCV Research UK was established by a grant from the Medical Research Foundation (award no: C0365). The award was made to the MRC-University of Glasgow Centre for Virus Research (CVR) [www.gla.ac.uk/researchinstitutes/ iii/cvr/].",
year = "2017",
month = "10",
doi = "10.1093/ije/dyw362",
language = "English",
volume = "46",
pages = "1391--1391h",
journal = "International Journal of Epidemiology",
issn = "0300-5771",
publisher = "Oxford University Press (OUP)",
number = "5",

}

McLauchlan, J, Innes, H, Dillon, J, Foster, G, Holtman, E, McDonald, S, Wilkes, B, Hutchinson, S & Irving, W 2017, 'Cohort profile: the hepatitis C virus (HCV) Research UK clinical database and biobank', International Journal of Epidemiology, vol. 46, no. 5, pp. 1391-1391h. https://doi.org/10.1093/ije/dyw362

Cohort profile: the hepatitis C virus (HCV) Research UK clinical database and biobank. / McLauchlan, John; Innes, Hamish; Dillon, John; Foster, Graham; Holtman, Elizabeth; McDonald, Sarah; Wilkes, Bryony ; Hutchinson, Sharon; Irving, Will .

In: International Journal of Epidemiology, Vol. 46, No. 5, 10.2017, p. 1391-1391h.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cohort profile: the hepatitis C virus (HCV) Research UK clinical database and biobank

AU - McLauchlan, John

AU - Innes, Hamish

AU - Dillon, John

AU - Foster, Graham

AU - Holtman, Elizabeth

AU - McDonald, Sarah

AU - Wilkes, Bryony

AU - Hutchinson, Sharon

AU - Irving, Will

N1 - Need to merge docs and re-upload Author confirmed version is AAM 23-1-17 Update: VoR uploaded as OA article ET 12-5-17 Funding to support this initiative was provided by the Medical Research Foundation, the independent charity of the UK Medical Research Council. HCV Research UK was established by a grant from the Medical Research Foundation (award no: C0365). The award was made to the MRC-University of Glasgow Centre for Virus Research (CVR) [www.gla.ac.uk/researchinstitutes/ iii/cvr/].

PY - 2017/10

Y1 - 2017/10

N2 - Cohort purpose: Chronic hepatitis C Virus (HCV) infection is a leading cause of liver disease, both in the UK and world-wide. The HCV Research UK clinical database and biobank was set up to tackle key gaps in our understanding of infection, particularly in relation to: the effectiveness and long-term impact of antiviral therapies; and the genetic/virological factors influencing the natural history of infection.Cohort Basics: The cohort comprises in excess of 10,000 participants. Each participant was enrolled between March 2012 and July 2015 following attendance at one of 56 specialist HCV clinics in the UK. The mean age at baseline is 48.5 years (range 0-88 years).Follow-up and attrition: A core set of follow-up data (covering health risk behaviours, physical characteristics, comorbidities, virology, co-medications, liver disease status, antiviral treatment and mortality status) will be collected from participants biennially. Additional follow-up data is being sought for strategic subgroups (e.g. selected participants with advanced liver disease). Design and Measures: This is a longitudinal cohort study. Baseline clinical and epidemiological data were collected through a standardised questionnaire completed by each participant at their enrolment. Follow-up data is elicited mainly through assessment of patient medical notes.Unique features: Participant blood samples have been stored in a biorespository and are available for research studies. Thus far, full-length next-generation sequencing of viral RNA, and host genotyping has been carried out in ~2000 and ~4000 cohort participants respectively. These data can be linked to the clinical/epidemiological data collected at baseline and follow-up.Reasons to be cautious: Participants included in this cohort represent ~50% of all patients in attendance at the selected recruitment clinics. Potentially, participants may differ from non-participants in epidemiologically/clinically relevant ways.Collaboration and data access : Data and samples are accessible to researchers following successful application to the HCV Research UK Tissue and Data Access Committee (TDAC). More information on the TDAC application process can be found at the HCV Research UK website - www.hcvresearchuk.org.

AB - Cohort purpose: Chronic hepatitis C Virus (HCV) infection is a leading cause of liver disease, both in the UK and world-wide. The HCV Research UK clinical database and biobank was set up to tackle key gaps in our understanding of infection, particularly in relation to: the effectiveness and long-term impact of antiviral therapies; and the genetic/virological factors influencing the natural history of infection.Cohort Basics: The cohort comprises in excess of 10,000 participants. Each participant was enrolled between March 2012 and July 2015 following attendance at one of 56 specialist HCV clinics in the UK. The mean age at baseline is 48.5 years (range 0-88 years).Follow-up and attrition: A core set of follow-up data (covering health risk behaviours, physical characteristics, comorbidities, virology, co-medications, liver disease status, antiviral treatment and mortality status) will be collected from participants biennially. Additional follow-up data is being sought for strategic subgroups (e.g. selected participants with advanced liver disease). Design and Measures: This is a longitudinal cohort study. Baseline clinical and epidemiological data were collected through a standardised questionnaire completed by each participant at their enrolment. Follow-up data is elicited mainly through assessment of patient medical notes.Unique features: Participant blood samples have been stored in a biorespository and are available for research studies. Thus far, full-length next-generation sequencing of viral RNA, and host genotyping has been carried out in ~2000 and ~4000 cohort participants respectively. These data can be linked to the clinical/epidemiological data collected at baseline and follow-up.Reasons to be cautious: Participants included in this cohort represent ~50% of all patients in attendance at the selected recruitment clinics. Potentially, participants may differ from non-participants in epidemiologically/clinically relevant ways.Collaboration and data access : Data and samples are accessible to researchers following successful application to the HCV Research UK Tissue and Data Access Committee (TDAC). More information on the TDAC application process can be found at the HCV Research UK website - www.hcvresearchuk.org.

KW - hepatitis C

KW - biobank

KW - liver disease

KW - host genomics

KW - cohort

KW - clinical database

U2 - 10.1093/ije/dyw362

DO - 10.1093/ije/dyw362

M3 - Article

VL - 46

SP - 1391-1391h

JO - International Journal of Epidemiology

JF - International Journal of Epidemiology

SN - 0300-5771

IS - 5

ER -